• Barinthus Biotherapeutics PLC BRNS.OQ reported a quarterly adjusted loss of 21 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -37 cents. The mean expectation of three analysts for the quarter was for a loss of 44 cents per share. Wall Street expected results to range from -49 cents to -41 cents per share.

• Revenue was $14.97 million​; analysts expected zero.

• Barinthus Biotherapeutics PLC's reported EPS for the quarter was a loss of 21 cents​.

• The company reported a quarterly loss of $8.11 million.

• Barinthus Biotherapeutics PLC shares had risen by 24.5% this quarter and lost 59.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 14.4% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Barinthus Biotherapeutics PLC is $7.00

This summary was machine generated from LSEG data November 7 at 03:09 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)